A Phase 2A, Investigator & Subject Blinded, Sponsor Unblinded, Placebo-Controlled, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
Latest Information Update: 24 Jul 2025
At a glance
- Drugs CRD 4730 (Primary)
- Indications Polymorphic catecholergic ventricular tachycardia
- Focus Adverse reactions
- Sponsors Cardurion Pharmaceuticals
Most Recent Events
- 14 Jul 2025 Status changed from recruiting to discontinued.
- 10 Jan 2025 Planned End Date changed from 31 Dec 2024 to 30 Sep 2025.
- 10 Jan 2025 Planned primary completion date changed from 29 Nov 2024 to 31 Jul 2025.